A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024 DOI Creative Commons
Zinnet Şevval Aksoyalp, Gizem Kaykı-Mutlu,

Leszek Wojnowski

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: March 31, 2025

Abstract The US Food and Drug Administration approved 50 new drugs nine cellular gene therapy products in 2024, i.e., a total of 59 medical therapies. latter group represented three treatments each for oncology hematology/immunotherapy, one neurology, genetic disorders, cardiovascular disorders. Oncology, neurological disorders (14, six, seven, respectively) also were highly prevalent among classic medications. Looking at trends over the past 5 years, we observe greater share first-in-class medications, more fast-track approvals, mRNA/gene/cell-based While small molecules remain largest fraction, their percentage has been declining substantially years. Taking together, these findings testify to commitment pharmaceutical industry innovative treatments, including conditions which no therapies existed. On other hand, there is trend approvals narrowly focused such as tumors defined by alterations.

Language: Английский

Assessment of targets of antibody drug conjugates in SCLC DOI Creative Commons

Abhishek Ajay,

Han Wang, Ali Reza Rezvani

et al.

npj Precision Oncology, Journal Year: 2025, Volume and Issue: 9(1)

Published: Jan. 2, 2025

Antibody-drug conjugate (ADC) therapy has transformed treatment for several solid tumors, including small cell lung cancer (SCLC). However, significant challenges remain, systemic toxicity, acquired resistance, and the lack of reliable biomarkers patient selection. To enhance effectiveness ADC therapies in SCLC, we focused on target selection this study by investigating expression targets - SEZ6, DLL3, CD276, TACSTD2 lines samples. SEZ6 was significantly elevated various SCLC transcriptional subtypes, particularly ASCL1, exhibited gender-specific differences, being lower women. DLL3 primarily observed ASCL1 subtype, while CD276 showed high non-neuroendocrine subtypes. levels were generally low attenuated lymph nodes brain metastases compared to primary tumors. Our findings underscore importance understanding patterns optimize advance precision medicine treatment.

Language: Английский

Citations

0
Pharmacological aspects of FDA-approved novel drug therapies against cancer in 2023: a comprehensive review DOI

Kavita Sangwan,

Parveen Kumar Goyal, Vipasha Sharma

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: March 11, 2025

Language: Английский

Citations

0
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024 DOI Creative Commons
Zinnet Şevval Aksoyalp, Gizem Kaykı-Mutlu,

Leszek Wojnowski

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: March 31, 2025

Abstract The US Food and Drug Administration approved 50 new drugs nine cellular gene therapy products in 2024, i.e., a total of 59 medical therapies. latter group represented three treatments each for oncology hematology/immunotherapy, one neurology, genetic disorders, cardiovascular disorders. Oncology, neurological disorders (14, six, seven, respectively) also were highly prevalent among classic medications. Looking at trends over the past 5 years, we observe greater share first-in-class medications, more fast-track approvals, mRNA/gene/cell-based While small molecules remain largest fraction, their percentage has been declining substantially years. Taking together, these findings testify to commitment pharmaceutical industry innovative treatments, including conditions which no therapies existed. On other hand, there is trend approvals narrowly focused such as tumors defined by alterations.

Language: Английский

Citations

0